In a dermal fibrosis model of SSc, treatment with a NR4A1 agonist, CsnB, leads to conversion of pro-inflammatory monocytes Ly6C+ monocytes to patrolling Ly6C- monocytes with NR4A1-dependent resolution of cutaneous fibrosis (80). Here, NR4A1 is linked to systemic sclerosis.